Somatostatin in Living Donor Liver Transplantation
Status:
Not yet recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Aim of the study is to investigate the safety and the efficacy of somatostatin as liver
inflow modulator in patients with end-stage liver disease (ESLD) and clinically significant
portal hypertension (CSPH) undergoing Adult-to-Adult living donor liver transplantation
(A2ALDLT).
Phase:
Phase 4
Details
Lead Sponsor:
King Faisal Specialist Hospital & Research Center
Collaborators:
CEINGE - Biotecnologie Avanzate, Napoli, Italia Federico II University of Naples, Department of Clinical Medicine and Surgery, Naples, Italy